View in EDS

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.

Saved in:
Bibliographic Details
Title: Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
Authors: Bender Ignacio RA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.; Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Moser C; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Eron JJ; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA., Javan AC; National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Giganti MJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Ritz J; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Gibbs M; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Kouekam HT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Daar ES; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, CA, USA., Choudhary M; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Deo R; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Fletcher CV; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA., Li JZ; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Hughes MD; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Smith D; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA., Wohl DA; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA.
Corporate Authors: ACTIV-2/A5401 Study Team
Source: IScience [iScience] 2025 Feb 04; Vol. 28 (3), pp. 111938. Date of Electronic Publication: 2025 Feb 04 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40124489
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bender+Ignacio+RA%22">Bender Ignacio RA</searchLink>; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.; Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Chew+KW%22">Chew KW</searchLink>; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Moser+C%22">Moser C</searchLink>; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Currier+JS%22">Currier JS</searchLink>; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Eron+JJ%22">Eron JJ</searchLink>; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Javan+AC%22">Javan AC</searchLink>; National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Giganti+MJ%22">Giganti MJ</searchLink>; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ritz+J%22">Ritz J</searchLink>; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gibbs+M%22">Gibbs M</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kouekam+HT%22">Kouekam HT</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Esser+MT%22">Esser MT</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Daar+ES%22">Daar ES</searchLink>; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Choudhary+M%22">Choudhary M</searchLink>; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Deo+R%22">Deo R</searchLink>; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fletcher+CV%22">Fletcher CV</searchLink>; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.<br /><searchLink fieldCode="AU" term="%22Li+JZ%22">Li JZ</searchLink>; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hughes+MD%22">Hughes MD</searchLink>; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Smith+D%22">Smith D</searchLink>; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wohl+DA%22">Wohl DA</searchLink>; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ACTIV-2%2FA5401+Study+Team%22">ACTIV-2/A5401 Study Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101724038%22">IScience</searchLink> [iScience] 2025 Feb 04; Vol. 28 (3), pp. 111938. <i>Date of Electronic Publication: </i>2025 Feb 04 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101724038 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2589-0042 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225890042%22">25890042 </searchLink><i>NLM ISO Abbreviation: </i>iScience <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40124489
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.isci.2025.111938
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 111938
    Titles:
      – TitleFull: Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bender Ignacio RA
      – PersonEntity:
          Name:
            NameFull: Chew KW
      – PersonEntity:
          Name:
            NameFull: Moser C
      – PersonEntity:
          Name:
            NameFull: Currier JS
      – PersonEntity:
          Name:
            NameFull: Eron JJ
      – PersonEntity:
          Name:
            NameFull: Javan AC
      – PersonEntity:
          Name:
            NameFull: Giganti MJ
      – PersonEntity:
          Name:
            NameFull: Ritz J
      – PersonEntity:
          Name:
            NameFull: Gibbs M
      – PersonEntity:
          Name:
            NameFull: Kouekam HT
      – PersonEntity:
          Name:
            NameFull: Esser MT
      – PersonEntity:
          Name:
            NameFull: Daar ES
      – PersonEntity:
          Name:
            NameFull: Choudhary M
      – PersonEntity:
          Name:
            NameFull: Deo R
      – PersonEntity:
          Name:
            NameFull: Fletcher CV
      – PersonEntity:
          Name:
            NameFull: Li JZ
      – PersonEntity:
          Name:
            NameFull: Hughes MD
      – PersonEntity:
          Name:
            NameFull: Smith D
      – PersonEntity:
          Name:
            NameFull: Wohl DA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 02
              Text: 2025 Feb 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2589-0042
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: IScience
              Type: main
ResultId 1